Skin Care and Beauty :Bristol drug extends survival in deadly skin cancer
Bristol-Myers Squibb Co’s experimental skin cancer drug ipilimumab added an average of four months to the lives of patients with advanced melanoma, U.S. researchers said on Saturday, representing a major advance in a disease littered with drug failures.
Melanoma is one of the Read the rest of this entry »